<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01925287</url>
  </required_header>
  <id_info>
    <org_study_id>01EA1334AHS1</org_study_id>
    <nct_id>NCT01925287</nct_id>
  </id_info>
  <brief_title>Oral Bioavailability of Curcumin From Micronized Powder and Liquid Micelles in Healthy Young Women and Men</brief_title>
  <official_title>Novel Strategies for the Enhancement of the Potency of Nutraceuticals With Low Oral Bioavailability and Their Application in Novel Functional Foods for Optimum Protection of the Aging Brain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hohenheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Hohenheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: The oral bioavailability of curcumin is low due to its limited intestinal uptake,
      rapid metabolism and excretion from the body. Considering its potent reported
      health-beneficial properties, researchers have tried to increase its bioavailability as a
      means to enhance its biological activities.

      Objective: The aim of the project was to develop novel curcumin formulations with enhanced
      oral bioavailability and to study the safety of the formulations and potential
      sex-differences in humans.

      Design: In this single-blind crossover study with three arms separated by â‰¥1-week washout
      periods, healthy subjects (13 women, 10 men) were provided standardized meals and took, in
      random order, a single oral dose of 500 mg curcumin as native powder, micronized powder, or
      liquid micelles. Blood and urine samples were collected in intervals for 24 h and total
      curcumin, demethoxycurcumin, and bis-demethoxycurcumin were quantified.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of total curcumin [nmol/L*h]</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8 and 24 h post-dose</time_frame>
    <description>Total curcumin was determined after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of total demethoxycurcumin [nmol/L*h]</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8 and 24 h post-dose</time_frame>
    <description>Total demethoxycurcumin was determined after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of total bisdemethoxycurcumin [nmol/L*h]</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8 and 24 h post-dose</time_frame>
    <description>Total bisdemethoxycurcumin was determined after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of total curcumin [nmol/L]</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8 and 24 h post-dose</time_frame>
    <description>Total curcumin was determined after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of total demethoxycurcumin [nmol/L]</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8 and 24 h post-dose</time_frame>
    <description>Total demethoxycurcumin was determined after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of total bisdemethoxycurcumin [nmol/L]</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8 and 24 h post-dose</time_frame>
    <description>Total bisdemethoxycurcumin was determined after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum plasma concentration (Tmax) of total curcumin [h]</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8 and 24 h post-dose</time_frame>
    <description>Total curcumin was determined after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum plasma concentration (Tmax) of total demethoxycurcumin [h]</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8 and 24 h post-dose</time_frame>
    <description>Total demethoxycurcumin was determined after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum plasma concentration (Tmax) of total bisdemethoxycurcumin [h]</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 8 and 24 h post-dose</time_frame>
    <description>Total bisdemethoxycurcumin was determined after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum aspartate transaminase activity [U/L]</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum aspartate transaminase activity [U/L]</measure>
    <time_frame>4 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum aspartate transaminase activity [U/L]</measure>
    <time_frame>24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum alanine transaminase activity [U/L]</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum alanine transaminase activity [U/L]</measure>
    <time_frame>4 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum alanine transaminase activity [U/L]</measure>
    <time_frame>24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum gamma-glutamyl transferase activity [U/L]</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum gamma-glutamyl transferase activity [U/L]</measure>
    <time_frame>4 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum gamma-glutamyl transferase activity [U/L]</measure>
    <time_frame>24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum alkaline phosphatase activity [U/L]</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum alkaline phosphatase activity [U/L]</measure>
    <time_frame>4 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum alkaline phosphatase activity [U/L]</measure>
    <time_frame>24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum bilirubin [mg/dL]</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum bilirubin [mg/dL]</measure>
    <time_frame>4 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum bilirubin [mg/dL]</measure>
    <time_frame>24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum uric acid [mg/dL]</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum uric acid [mg/dL]</measure>
    <time_frame>4 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum uric acid [mg/dL]</measure>
    <time_frame>24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cystatin C [mg/L]</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cystatin C [mg/L]</measure>
    <time_frame>4 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cystatin C [mg/L]</measure>
    <time_frame>24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate [mL/min]</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate [mL/min]</measure>
    <time_frame>4 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate [mL/min]</measure>
    <time_frame>24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine [mg/dL]</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine [mg/dL]</measure>
    <time_frame>4 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine [mg/dL]</measure>
    <time_frame>24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total cholesterol [mg/dL]</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total cholesterol [mg/dL]</measure>
    <time_frame>4 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total cholesterol [mg/dL]</measure>
    <time_frame>24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum HDL cholesterol [mg/dL]</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum HDL cholesterol [mg/dL]</measure>
    <time_frame>4 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum HDL cholesterol [mg/dL]</measure>
    <time_frame>24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum LDL cholesterol [mg/dL]</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum LDL cholesterol [mg/dL]</measure>
    <time_frame>4 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum LDL cholesterol [mg/dL]</measure>
    <time_frame>24 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum triacylglycerols [mg/dL]</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum triacylglycerols [mg/dL]</measure>
    <time_frame>4 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum triacylglycerols [mg/dL]</measure>
    <time_frame>24 h post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Pharmacokinetics of Novel Curcumin Formulations</condition>
  <condition>Safety of Novel Curcumin Formulations</condition>
  <arm_group>
    <arm_group_label>Native curcumin powder</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 mg curcumin as native powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Micronized curcumin powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg curcumin as micronized powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Curcumin micelles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg curcumin incorporated into liquid micelles</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>curcumin</intervention_name>
    <description>500 mg curcumin were given orally either as native powder, micronized powder, or liquid micelles</description>
    <arm_group_label>Native curcumin powder</arm_group_label>
    <arm_group_label>Micronized curcumin powder</arm_group_label>
    <arm_group_label>Curcumin micelles</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers with routine blood chemistry values within the normal ranges

        Exclusion Criteria:

          -  overweight (BMI &gt;30 kg/m2)

          -  metabolic and endocrine diseases

          -  pregnancy

          -  lactation

          -  drug abuse

          -  use of dietary supplements or any form of medication (with the exception of oral
             contraceptives)

          -  smoking

          -  frequent alcohol consumption (&gt;20 g ethanol/d)

          -  adherence to a restrictive dietary regimen

          -  physical activity of more than 5 h/wk

          -  participation in a clinical trial within the past 3 months prior to recruitment

          -  known intolerance against curcuma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Frank, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hohenheim, Stuttgart, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Hohenheim</name>
      <address>
        <city>Stuttgart</city>
        <zip>70599</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.nutrition-research.de/</url>
    <description>Website of the research group</description>
  </link>
  <results_reference>
    <citation>Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, Frank J. The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res. 2014 Mar;58(3):516-27. doi: 10.1002/mnfr.201300724. Epub 2014 Jan 9. Erratum in: Mol Nutr Food Res. 2014 Mar;58(3):647. Dosage error in article text.</citation>
    <PMID>24402825</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2013</study_first_submitted>
  <study_first_submitted_qc>August 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2013</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bioavailability</keyword>
  <keyword>curcumin</keyword>
  <keyword>curcuma longa</keyword>
  <keyword>healthy humans</keyword>
  <keyword>safety</keyword>
  <keyword>sex differences</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

